Jason Robins was appointed as Chief Financial Officer at OCULAR THERAPEUTIX, INC.
“On June 10, 2026, the Board appointed Jason Robins, the Company’s interim Chief Financial Officer, to serve as the Chief Financial Officer.”
OCULAR THERAPEUTIX, INC — fact timeline
Source-grounded facts extracted from OCULAR THERAPEUTIX, INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OCULAR THERAPEUTIX, INC shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-12-31 meeting.
“The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”
OCULAR THERAPEUTIX, INC shareholders approved Amendment No. 5 to increase shares under the 2021 Stock Incentive Plan by 10,000,000 shares.
“The Company’s stockholders approved Amendment No. 5 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 10,000,000 shares.”
OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory vote on frequency of future advisory votes to approve named executive officer compensation.
“The Company’s stockholders approved, on a non-binding, advisory basis, “One Year” for the frequency of future advisory votes to approve the compensation of the Company’s named executive officers.”
OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory vote to approve the compensation of the Company's named executive officers.
“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2026 Proxy Statement.”
OCULAR THERAPEUTIX, INC shareholders approved Election of Pravin U. Dugel, M.D. and Merilee Raines as Class III directors to serve until the 2029 Annual Meeting.
“The Company’s stockholders elected Pravin U. Dugel, M.D. and Merilee Raines as Class III directors to serve until the 2029 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
OCULAR THERAPEUTIX, INC reported financial results for first quarter ended March 31, 2026.
“On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026.”
OCULAR THERAPEUTIX, INC: Amended restated certificate of incorporation to provide for officer exculpation (effective 2025-06-11).
“At the 2025 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), to update its existing director exculpation provision to include the exculpation of certain of the Company’s senior corporate officers, subject to specified limitations. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 11, 2025.”
Donald Notman was appointed as Chief Operating Officer at OCULAR THERAPEUTIX, INC.
“On August 29, 2024, the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Donald Notman to serve as Chief Operating Officer of the Company.”
OCULAR THERAPEUTIX, INC announced a restructuring with charges of approximately $1.0 to $2.0 million affecting research and development and technical operations (37 full-time employees).
“reduction in force and to record the related restructuring charges in the second quarter of 2024. The Company anticipates incurring total restructuring costs of approximately $1.0 to $2.0 million, which includes garden leave, severance benefits and related costs and which are expected to result in cash expenditures during the second and third quarters of”
OCULAR THERAPEUTIX, INC reported first quarter ended March 31, 2024 results: revenue $14.8 million, net income $(64.8) million, EPS $(0.49) per share.
“Company believes that its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028. Total net revenue was $14.8 million for the first quarter of 2024, a 10.4% increase over total net revenue of $13.4 million in the comparable period in 2023, driven by increased DEXTENZA sales. Total net revenue”
Rabia Gurses Ozden, M.D. departed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
“Effective upon the commencement of Dr. Waheed’s employment, Rabia Gurses Ozden, M.D., will cease to serve as the company’s Chief Medical Officer.”
Nadia Waheed, M.D. was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
“On April 16, 2024, the Company announced that Nadia Waheed, M.D., had been appointed to serve as Chief Medical Officer of the Company, effective upon the anticipated commencement of her employment with the Company on May 20, 2024.”
Antony C. Mattessich resigned as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.
“On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.”
Pravin U. Dugel, M.D. was appointed as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.
“On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.”
OCULAR THERAPEUTIX, INC reported the full year ended December 31, 2023 results: revenue $58.4 million.
“Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%.”
OCULAR THERAPEUTIX, INC reported the fourth quarter 2023 results: revenue $14.8 million, net income $(29.2) million, EPS $(0.35) per share on both a basic and diluted basis.
“Total net revenue was $14.8 million for the fourth quarter of 2023, a 5.0% increase over total net revenue of $14.1 million in the comparable period in 2022, driven by DEXTENZA sales. Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%. Research and development expenses for the fourth quarter of 2023 were $16.2 million versus $13.5 million for the comparable period in 2022, driven primarily by an increase in overall clinical and regulatory expenses associated with product development programs. Overall R&D expenses for the full year increased $7.6 million to $61.1 million from $53.5 million in 2022, reflecting the timing and conduct of our clinical trials. Selling and marketing expenses were $9.2 million in the fourth quarter of 2023, as compared to $10.5 million for the comparable quarter of 2022, primarily reflecting a reduction in personnel costs driven by lower expense for stock-based compensation and other items. Overall, se”
OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2023 results: revenue approximately $57.9 million.
“its preliminary, unaudited cash and cash equivalents were approximately $195.8 million as of December 31, 2023, and its preliminary, unaudited net product revenue for the year ended December 31, 2023, was approximately $57.9 million.”
OCULAR THERAPEUTIX, INC entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $325.0 million (effective 2024-02-21).
“On February 21, 2024, Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 32,413,560 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $7.52 per share and, to certain Investors in lieu of Shares, pre-funded warrants to purchase 10,805,957 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $7.519 per Pre-Funded Warrant (the “Private Placement”).”
Pravin U. Dugel, M.D. was appointed as Executive Chairman at OCULAR THERAPEUTIX, INC.
“On February 20, 2024, Pravin U. Dugel, M.D., was appointed as Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024”
OCULAR THERAPEUTIX, INC entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at public offering price of $3.25 per share (effective 2023-12-13).
“On December 13, 2023, Ocular Therapeutix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 30,800,000 shares (the “Firm Shares”) of the Company’s common stock”
OCULAR THERAPEUTIX, INC reported third quarter ended September 30, 2023 results: revenue $15.0 million.
“Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early April 2024 DEXTENZA ® Net Product Revenue in Q3 2023 was $15.0 million, Representing Growth of Approximately 26% Over Q3 2022 BEDFORD, Mass.–(BUSINESS WIRE)— November 7, 2023 – Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company”
OCULAR THERAPEUTIX, INC reported financial results for the second quarter ended June 30, 2023.
“On August 7, 2023, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2023.”
Adrienne L. Graves was elected as member of the Board at OCULAR THERAPEUTIX, INC.
“On July 10, 2023 (the “Effective Date”), the board of directors (the “Board”) of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Adrienne L. Graves, Ph.D., to serve as a member of the Board, effective immediately.”
OCULAR THERAPEUTIX, INC amended Third Amendment with Cobalt PropCo 2020, LLC valued at approximately $1.5 million (effective 2023-06-30).
“On June 30, 2023, Ocular Therapeutix, Inc. (the “Company”) and Cobalt PropCo 2020, LLC, as successor-in-interest to CCC Investors LLC, entered into an amendment (the “Third Amendment”) to a lease agreement for the Company’s manufacturing space located at 36 Crosby Drive in Bedford, Massachusetts (the “Premises”). The Third Amendment further amends the original lease agreement, by and between the Company and Cobalt PropCo 2020, LLC (as successor-in-interest to CCC Investors LLC (as successor-in-interest to RAR2-Crosby Corporate Center QRS, Inc.)), dated as of September 2, 2009 (as amended to date, the “Lease”). The Third Amendment extends the term of the Lease, which had been scheduled to expire on July 31, 2023, to July 31, 2028. Under the Third Amendment, the annual base rent for the Premises shall be $0 from August 1, 2023 to September 30, 2023, and shall be approximately $1.5 million from October 1, 2023 to July 31, 2024.”
OCULAR THERAPEUTIX, INC shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
“The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2023.”
OCULAR THERAPEUTIX, INC shareholders approved Amendment No. 2 to increase shares under the 2021 Stock Incentive Plan by 3,900,000 shares.
“The Company’s stockholders approved Amendment No. 2 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 3,900,000 shares.”
OCULAR THERAPEUTIX, INC shareholders approved Non-binding advisory proposal regarding compensation of named executive officers.
“The Company’s stockholders approved a non-binding, advisory proposal regarding the compensation of the Company’s named executive officers.”
OCULAR THERAPEUTIX, INC shareholders approved Election of Class III directors.
“The Company’s stockholders elected Jeffrey S. Heier, M.D. and Merilee Raines as Class III directors to serve until the 2026 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
OCULAR THERAPEUTIX, INC reported the first quarter ended March 31, 2023 results: revenue $13.2 million. Guidance reaffirmed.
“Net product revenue of DEXTENZA for the first quarter of 2023 was $13.2 million”
OCULAR THERAPEUTIX, INC amended Amendment to Fourth Amended and Restated Credit and Security Agreement with MidCap Financial Trust, as administrative agent, and the lenders party thereto (effective 2023-03-31).
“the Company, the Administrative Agent, and the Lenders entered into an amendment to the Agreement on March 31, 2023 (the “Amendment”), to replace the LIBOR-based interest rate provisions of the Agreement with SOFR-based interest rate provisions, establish a benchmark replacement mechanism and make additional administrative updates.”
OCULAR THERAPEUTIX, INC reported the fourth quarter and year ended December 31, 2022 results: revenue $51.5 million.
“intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2023 Total Net Revenue for Full Year 2022 was $51.5 million, Representing Growth of 18% Over the Prior Year DEXTENZA ® Net Product Revenue in the Fourth Quarter of 2022 was $13.9 million, Representing Growth of approximately 17% Over”
OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2022 results: revenue net product revenue for the fourth quarter of 2022 is estimated to be $13.6 million.
“the Company disclosed in the Release preliminary estimates as to net product revenue for the quarter and year ended December 31, 2022 and cash and cash equivalents as of December 31, 2022.”
OCULAR THERAPEUTIX, INC updated its the quarter ended September 30, 2022 guidance (reaffirmed).
“On November 7, 2022, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2022.”
Rabia Gurses Ozden was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
“In connection with his departure, Rabia Gurses Ozden, M.D., Senior Vice President, Clinical Development of the Company, has agreed to assume the role of Chief Medical Officer of the Company, effective on July 1, 2022.”
Michael Goldstein departed as President, Ophthalmology and Chief Medical Officer at OCULAR THERAPEUTIX, INC.
“On June 3, 2022, Michael Goldstein, M.D., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, Inc. (the “Company”) and the Company mutually agreed that Dr. Goldstein would depart the Company to pursue other business opportunities, effective June 30, 2022 (the “Separation Date”).”
Bruce A. Peacock departed as Director at OCULAR THERAPEUTIX, INC.
“On February 3, 2022, Bruce A. Peacock notified Ocular Therapeutix, Inc. (the “Company”) that he planned to resign as a member of the Board of Directors on the date of the Company’s annual meeting of stockholders to be held in 2022.”
Merilee Raines was elected as Director at OCULAR THERAPEUTIX, INC.
“elected Merilee Raines to serve as a member of the Board to fill a vacancy on the Board”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.